Karyopharm Therapeutics Inc.
KPTIHealthcare|Biotechnology|US
$0.05
-0.01 (-8.65%)
Cash / Share
$2.25
Clinical Trials (95)
| Trial | Conditions | Phase | Status | Enrollment | Design | Drug |
|---|---|---|---|---|---|---|
| NCT04562389 Study of Selinexor in Combination With Ruxolitinib in Myelofibrosis | Myelofibrosis | P3 | Active | 353 | RCT, Double-blind | Selinexor, Selinexor, Ruxolitinib |
| NCT05611931 Selinexor in Maintenance Therapy After Systemic Therapy for Participants With p53 Wild-Type, Advanced or Recurrent Endometrial Carcinoma | Endometrial Cancer | P3 | Active | 257 | RCT, Double-blind | Selinexor, Matching Placebo for selinexor |
| NCT04442022 A Study of Rituximab-Gemcitabine-Dexamethasone-Platinum (R-GDP) With or Without Selinexor in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma | Relapsed/Refractory Diffuse Large B-cell Lymphoma | P2P3 | Active | 501 | RCT, Double-blind | Selinexor (combination therapy), Selinexor (combination therapy), Selinexor (combination therapy), Placebo matching for Selinexor (combination therapy), Rituximab (combination therapy), Rituximab (combination therapy), Gemcitabine (combination therapy), Dexamethasone (combination therapy), Cisplatin (combination therapy), Selinexor (continuous therapy), Placebo matching for Selinexor (continuous therapy) |
| NCT05028348 A Study of Combination of Selinexor, Pomalidomide, and Dexamethasone (SPd) Versus Elotuzumab, Pomalidomide, and Dexamethasone (EloPd) in Subject With Previously Treated Multiple Myeloma | Multiple Myeloma | P3 | Active | 117 | RCT, Open-label | Selinexor, Elotuzumab, Pomalidomide, Dexamethasone Oral |
| NCT02436707 Novel Combination Therapy in the Treatment of Relapsed and Refractory Aggressive B-Cell Lymphoma | Lymphoma | P2 | Active | 129 | RCT, Open-label | Ibrutinib, Rituximab, Gemcitabine, Dexamethasone, Cisplatin, Mesna, Cyclophosphamide, Etoposide, G-CSF, Selinexor |
| NCT02227251 Selinexor (KPT-330) in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL) | Diffuse Large B-cell Lymphoma | P2 | Active | 244 | RCT, Open-label | Selinexor, Selinexor, Selinexor |
| NCT05983276 Decitabine and Selinexor in Combination to Reverse Drug Resistance With Standard Chemotherapy in Ovarian Cancer | Ovarian Cancer | P2 | Recruiting | 40 | Open-label | Decitabine, Carboplatin, Paclitaxel, Selinexor |
| NCT04782687 Study of Selinexor Plus DRd for Newly Diagnosed Multiple Myeloma | Multiple Myeloma, Myeloma Multiple | P2 | Active | 73 | Open-label | Selinexor, Dexamethasone Oral, Daratumumab, Lenalidomide |
| NCT02343042 Selinexor and Backbone Treatments of Multiple Myeloma Patients | Multiple Myeloma | P1P2 | Recruiting | 300 | RCT, Open-label | Selinexor, Dexamethasone, Lenalidomide, Pomalidomide, Bortezomib, Daratumumab, Carfilzomib, Ixazomib, Elotuzumab, Clarithromycin, Belantamab Mafodotin, Mezigdomide |
| NCT04661137 A Study of Selinexor, in Combination With Carfilzomib, Daratumumab or Pomalidomide in Patients With Multiple Myeloma | Multiple Myeloma | P2 | Recruiting | 96 | Open-label | Selinexor 60 MG, Selinexor 80 MG, Selinexor 100 MG, Carfilzomib, Pomalidomide, Daratumumab, Dexamethasone |
| NCT07479979 Study of Selinexor With Carfilzomib, Isatuximab and Dexamethasone for Patients With Relapsed and/or Refractory Multiple Myeloma | Relapse Multiple Myeloma, Refractory Multiple Myeloma | P1P2 | Recruiting | 62 | Open-label | Selinexor, Carfilzomib, Isatuximab, Dexamethasone |
| NCT05530421 Selinexor, Venetoclax, and Dexamethasone (XVenD) in t(11;14)-Positive Relapsed/Refractory Multiple Myeloma | Relapsed and Refractory Multiple Myeloma | P2 | Recruiting | 33 | Open-label | Selinexor, Venetoclax, Dexamethasone |
| NCT05980806 A Study of Selinexor Monotherapy in Subjects With JAK Inhibitor-naïve Myelofibrosis and Moderate Thrombocytopenia | Myelofibrosis, Moderate Thrombocytopenia | P2 | Recruiting | 58 | Open-label | Selinexor 60 mg, Selinexor 40 mg, Ruxolitinib, Pacritinib, Momelotinib |
| NCT04414475 A Study of Selinexor (Seli) + Low-dose Dexamethasone (LDD) in Penta-refractory Multiple Myeloma (MM), Seli and Bortezomib + LDD in Triple-class Refractory MM. | Multiple Myeloma, Refractory | P2 | Recruiting | 127 | RCT, Open-label | Selinexor, Dexamethasone, Bortezomib |
| NCT04717700 Selinexor With Alternating Bortezomib or Lenalidomide Plus Dexamethasone in TIE Newly Diagnosed MM Patients | Multiple Myeloma | P2 | Active | 50 | Open-label | Selinexor 20 MG Oral Tablet, Bortezomib Injection, Lenalidomide capsule, Dexamethasone Oral |
| NCT07447817 Selinexor and Pacritinib in JAK Inhibitor-naïve MF Patients With Cytopenias | Myelofibrosis, Post-polycythemia Vera Myelofibrosis | P2 | Recruiting | 26 | Open-label | Pacritinib, Selinexor |
| NCT04562870 A Study to Evaluate Single Agent Selinexor Versus Physician's Choice in Participants With Previously Treated Myelofibrosis | Myelofibrosis | P2 | Active | 112 | RCT, Open-label | Selinexor |
| NCT04925193 Personalized Selinexor-based Therapy for Relapsed/Refractory Multiple Myeloma | Multiple Myeloma in Relapse | P2 | Active | 18 | Open-label | Selinexor, Pomalidomide, Daratumumab, Carfilzomib, Dexamethasone |
| NCT05597345 Selinexor for the Treatment of Intermediate and High-Risk Smoldering Multiple Myeloma | Smoldering Multiple Myeloma | P2 | Recruiting | 15 | Open-label | Selinexor |
| NCT06399640 Eltanexor and Venetoclax in Relapsed or Refractory Myelodysplastic Syndrome and Acute Myeloid Leukemia | Relapsed Myelodysplastic Syndrome, Refractory Myelodysplastic Syndrome | P1 | Recruiting | 60 | Open-label | Eltanexor, Venetoclax |
| NCT02091245 Phase I Trial of the Selective Inhibitor of Nuclear Export, KPT-330, in Relapsed Childhood ALL and AML | Relapsed Acute Lymphoblastic Leukemia (ALL), Refractory Acute Lymphoblastic Leukemia (ALL) | P1 | Active | 16 | Open-label | KPT-330 |
| NCT07200102 Selinexor Maintenance Post CAR-T Cell Therapy for Multiple Myeloma | Multiple Myeloma | P1 | Recruiting | 20 | Open-label | Selinexor |
| NCT04898894 Study of Selinexor and Venetoclax in Combination With Chemotherapy in Pediatric and Young Adult Patients With Refractory or Relapsed Acute Myeloid Leukemia | Acute Leukemia of Ambiguous Lineage in Relapse, Acute Myeloid Leukemia, in Relapse | P1 | Active | 37 | Open-label | Venetoclax, Selinexor, Cytarabine, Fludarabine, Filgrastim, Methotrexate, methotrexate/hydrocortisone/cytarabine |
| NCT07362225 MPN PROGRESSion Registry: Observational Study Tracking Symptoms, Treatments, and Disease Progression in People With Myeloproliferative Neoplasms (MPNs) | Polycythemia Vera, ET (Essential Thrombocythemia) | Recruiting | 5,000 | — | — | |
| NCT03110562 Bortezomib, Selinexor, and Dexamethasone in Patients With Multiple Myeloma | Multiple Myeloma | P3 | Completed | 402 | RCT, Open-label | Selinexor, Bortezomib, Dexamethasone |
| NCT02606461 Selinexor in Advanced Liposarcoma | Dedifferentiated Liposarcoma | P2P3 | Completed | 342 | RCT, Double-blind | Selinexor, Placebo |
| NCT03555422 Maintenance With Selinexor/Placebo After Combination Chemotherapy in Participants With Endometrial Cancer [SIENDO] | Endometrial Cancer | P3 | Completed | 263 | RCT, Double-blind | Selinexor, Matching placebo for selinexor |
| NCT02228525 Selective Inhibitor of Nuclear Export (SINE) Selinexor (KPT-330) in Patients With Myelodysplastic Syndromes | Myelodysplastic Syndromes | P2 | Completed | 25 | Open-label | selinexor (KPT-330) |
| NCT02088541 Selinexor (KPT-330) in Older Patients With Relapsed AML | Acute Myeloid Leukemia (AML) | P2 | Completed | 317 | RCT, Open-label | Selinexor, Hydroxyurea, Ara-C |
| NCT02649790 Study of the Safety, Tolerability and Efficacy of KPT-8602 in Participants With Relapsed/Refractory Cancer Indications | Relapsed/Refractory Multiple Myeloma (RRMM), Metastatic Colorectal Cancer (mCRC) | P1P2 | Completed | 277 | Open-label | KPT-8602, ASTX727, Dexamethasone |
| NCT01986348 Study Evaluating the Efficacy and Safety of Selinexor (KPT-330) in Participants With Recurrent Gliomas | Glioblastoma, Glioma | P2 | Terminated | 76 | RCT, Open-label | Selinexor |
| NCT04856189 Selinexor and Pembrolizumab for the Treatment of Cisplatin-Ineligible or Cisplatin-Refractory Locally Advanced or Metastatic Urothelial Carcinoma | Advanced Urothelial Carcinoma, Locally Advanced Urothelial Carcinoma | P1P2 | Terminated | 4 | Open-label | Pembrolizumab, Selinexor |
| NCT02431351 Efficacy & Safety Study of KPT-330 in Erythropoietin-Refractory Lower-Risk Myelodysplastic Syndrome Patients | Myelodysplastic Syndrome | P2 | Withdrawn | — | Open-label | Selinexor |
| NCT03095612 Phase 1/2 Trial of Selinexor (KPT-330) With Docetaxel for Non-small Cell Lung Cancer (NSCLC) | Non-small Cell Lung Cancer | P1P2 | Terminated | 41 | Open-label | Selinexor, Docetaxel |
| NCT02249091 A Phase II Study of Selinexor Plus Cytarabine and Idarubicin in Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML) | Acute Myeloid Leukemia (Relapsed/Refractory) | P2 | Completed | 42 | Open-label | Selinexor, Idarubicin, Cytarabine |
| NCT03193437 Selinexor in Patients With Advanced Thymic Epithelial Tumor Progressing After Primary Chemotherapy | Thymoma, Advanced Thymic Epithelial Tumor | P2 | Terminated | 8 | Open-label | Open Label Selinexor |
| NCT03071276 Selinexor in Combination With Fludarabine and Cytarabine in Patients With Refractory or Relapsed Acute Myeloid Leukemia | Acute Myeloid Leukemia (AML) | P2 | Terminated | 37 | Open-label | Selinexor, Fludarabine, Cytarabine, methotrexate/hydrocortisone/cytarabine |
| NCT03627403 Selinexor in Myelofibrosis Refractory or Intolerant to JAK1/2 Inhibitors | Primary Myelofibrosis, Post-essential Thrombocythemia Myelofibrosis | P2 | Terminated | 17 | Open-label | Selinexor |
| NCT02025985 Study of KPT-330 (Selinexor) in Female Patients With Advanced Gynaecologic Malignancies | Ovarian Carcinoma, Endometrial Carcinoma | P2 | Completed | 116 | RCT, Open-label | Selinexor |
| NCT05177276 Selinexor Combination Ph 1 Study | Solid Tumor Malignancy | P1P2 | Withdrawn | — | Open-label | Selinexor, Irinotecan |
| NCT02138786 Selinexor in Initial or Refractory and/or Relapsed Richter's Transformation | Richter's Transformation | P2 | Terminated | 27 | Open-label | selinexor |
| NCT07832227 Imlunestrant/Abemaciclib/Selinexor in Ovarian and Endometrial | Low Grade Ovarian Serous Adenocarcinoma, Endometrial Cancer | P2 | Not Yet Recruiting | 60 | Open-label | Imlunestrant, Abemaciclib, Selinexor |
| NCT02314247 Efficacy and Safety Study of Selinexor in Relapsed or Refractory Peripheral T-cell Lymphoma or Cutaneous T-cell Lymphoma | Peripheral T-cell Lymphoma (PTCL), Cutaneous T-cell Lymphoma (CTCL) | P2 | Terminated | 16 | Open-label | Selinexor |
| NCT04854434 A Study to Evaluate the Safety and Efficacy of Selinexor With or Without Pembrolizumab Versus Standard of Care in Previously Treated Metastatic Colorectal Cancer With RAS Mutations | Metastatic Colorectal Cancer | P2 | Terminated | 13 | RCT, Open-label | Selinexor, Pembrolizumab, Trifluridine, Tipiracil |
| NCT02402764 Phase 2 Trial of Selinexor (KPT-330) for Metastatic Triple Negative Breast Cancer (TNBC) | Breast Cancer | P2 | Completed | 10 | Open-label | Selinexor |
| NCT02367690 Study of Safety, Tolerability, and Pharmacokinetics of Topical Selinexor (KPT-330) Diabetic Foot Ulcer (DFU) Patients | Diabetic Foot Ulcers | P1P2 | Withdrawn | — | RCT, Single-blind | Selinexor |
| NCT03732703 Myeloma-Developing Regimens Using Genomics (MyDRUG) | Relapsed Refractory Multiple Myeloma | P1P2 | Completed | 103 | Open-label | Abemaciclib, dexamethasone, ixazomib, pomalidomide, Enasidenib, dexamethasone, ixazomib, pomalidomide, Cobimetinib, dexamethasone, ixazomib, pomalidomide, Erdafitinib, dexamethasone, ixazomib, pomalidomide, Venetoclax, dexamethasone, ixazomib, pomalidomide, Daratumumab, dexamethasone, ixazomib, pomalidomide, Belantamab mafodotin, dexamethasone, ixazomib, pomalidomide, Selinexor, dexamethasone, ixazomib, pomalidomide |
| NCT03191981 Pembrolizumab Cyclophosphamide and Lenalidomide for Patients With Relapsed Multiple Myeloma | Myeloma Multiple | P1P2 | Withdrawn | — | Open-label | Cyclophosphamide, Lenalidomide, Pembrolizumab |
| NCT02250885 KPT-330 to Treat Poorly Differentiated Lung and Gastroenteropancreatic Tumors | Carcinoma, Neuroendocrine | P2 | Completed | 14 | Open-label | Selinexor |
| NCT04843579 Treatment of Selinexor in Combination With Clarithromycin, Pomalidomide and Dexamethasone for Relapsed Refractory Multiple Myeloma Patients | Myeloma Multiple, Myeloma | P2 | Terminated | 4 | Open-label | Selinexor, Clarithromycin, Pomalidomide, Dexamethasone |
| NCT05820763 Selinexor and Lenalidomide for Consolidation and Maintenance Treatment in Multiple Myeloma Post-transplant | Multiple Myeloma, Myeloma-Associated Amyloidosis | P2 | Withdrawn | — | Open-label | Selinexor, Lenalidomide, Dexamethasone |
| NCT05170789 Elotuzumab, Selinexor, and Dexamethasone for Relapsed Refractory Multiple Myeloma | Relapsed Multiple Myeloma, Refractory Multiple Myeloma | P2 | Withdrawn | — | Open-label | Elotuzumab, Selinexor, and Dexamethasone (ESd) |
| NCT04607772 Study of Selinexor in Combination With Backbone Treatments or Novel Therapies In Participants With Relapsed or Refractory (RR) Diffuse Large B-Cell Lymphoma (DLBCL) | Relapsed or Refractory Diffuse Large B-Cell Lymphoma | P1P2 | Withdrawn | — | Open-label | Selinexor, Rituximab, Bendamustine, Polatuzumab Vedotin, Ibrutinib, Lenalidomide, Tafasitamab, Venetoclax, Gemcitabine, Oxaliplatin |
| NCT02213133 Selinexor Treatment of Advanced Relapsed/Refractory Squamous Cell Carcinomas | Squamous Cell Carcinoma | P2 | Terminated | 45 | Open-label | Selinexor (KPT-330) |
| NCT02336815 Selinexor Treatment of Refractory Myeloma | Multiple Myeloma | P2 | Completed | 202 | Open-label | Selinexor, Dexamethasone |
| NCT02416908 Study of CLAG + Selinexor in Relapsed or Refractory Acute Myeloid Leukemia | Acute Myeloid Leukemia | P1P2 | Completed | 40 | Open-label | Selinexor, Cladribine, G-CSF, Cytarabine |
| NCT04421378 A Study of Selinexor in Combination With Standard of Care Therapy for Newly Diagnosed or Recurrent Glioblastoma | Glioblastoma Multiforme | P1P2 | Terminated | 74 | RCT, Open-label | Selinexor, Temozolomide (TMZ), Lomustine (CCNU), Bevacizumab, Carmustine |
| NCT04355676 Evaluation of Activity and Safety of Two Regimens of Low Dose Oral Selinexor in Participants With Moderate or Severe COVID-19 | Coronavirus Infection | P2 | Withdrawn | — | RCT, Open-label | Selinexor |
| NCT02146833 SHIP (Selinexor in Hormone Insensitive Prostate Cancer) | Prostate Cancer | P2 | Terminated | 20 | RCT, Open-label | Selinexor |
| NCT02628704 Selinexor, Carfilzomib, and Dexamethasone Versus Placebo, Carfilzomib, and Dexamethasone in Multiple Myeloma | Multiple Myeloma | P2 | Withdrawn | — | RCT, Double-blind | Selinexor, Placebo (for selinexor), carfilzomib, Dexamethasone |
| NCT02530476 Phase I/II, Study of Selective Inhibitor of Nuclear Export (SINE) Selinexor (KPT-330) + Sorafenib in Acute Myeloid Leukemia | Leukemia, Acute Myeloid Leukemia | P1P2 | Completed | 17 | Open-label | Selinexor, Sorafenib |
| NCT02780609 Selinexor Plus High-Dose Melphalan (HDM) Before Autologous Hematopoietic Cell Transplantation for Multiple Myeloma | Multiple Myeloma | P1P2 | Completed | 22 | Open-label | Selinexor, Melphalan, Dexamethasone, Fosaprepitant |
| NCT04256707 Relative Bioavailability/Bioequivalence of Different Formulations of Selinexor, the Impact of Hepatic Impairment on Selinexor Pharmacokinetics, Tolerability and Antitumor Activity of Selinexor Combination Treatment | Non-Small Cell Lung Carcinoma (NSCLC), Colorectal Cancer (CRC) | P1P2 | Completed | 80 | RCT, Open-label | Selinexor 100 mg, Docetaxel, Pembrolizumab, FOLFIRI, Selinexor 40 mg, Selinexor 80 mg, Selinexor 60 mg |
| NCT02351505 Selinexor in Treating Patients With Relapsed Small Cell Lung Cancer | Recurrent Small Cell Lung Carcinoma | P2 | Terminated | 1 | Open-label | Selinexor |
| NCT03466827 Selinexor in Patients With Advanced Thymoma and Thymic Carcinoma | Thymoma, Advanced Thymic Epithelial Tumour | P2 | Unknown | 25 | Open-label | Selinexor |
| NCT02186834 Selinexor (KPT-330) and Liposomal Doxorubicin For Relapsed and Refractory Multiple Myeloma | Multiple Myeloma | P1P2 | Completed | 28 | Open-label | Selinexor, Liposomal doxorubicin, Dexamethasone |
| NCT04768881 Safety and Efficacy of Selinexor in Combination With Pembrolizumab in Recurrent Advanced Melanoma | Locally Advanced Unresectable or Metastatic Melanoma | P2 | Terminated | 15 | RCT, Open-label | Selinexor, Pembrolizumab |
| NCT02536495 Selinexor and Docetaxel in Treating Patients With Recurrent or Metastatic Squamous Cell Lung Cancer | Recurrent Squamous Cell Lung Carcinoma, Stage IV Squamous Cell Lung Carcinoma | P1P2 | Withdrawn | — | Open-label | Docetaxel, Selinexor |
| NCT04349098 Evaluation of Activity and Safety of Oral Selinexor in Participants With Severe COVID-19 Infection | Coronavirus Infection | P2 | Completed | 190 | RCT, Single-blind | Selinexor |
| NCT02389543 Study of Selinexor (KPT- 330), Lenalidomide, & Dexamethasone in Relapsed/Refractory Multiple Myeloma Patients | Multiple Myeloma | P1P2 | Withdrawn | — | RCT, Open-label | Selinexor, Lenalidomide, Dexamethasone |
| NCT01607905 Safety Study of KPT-330 (Selinexor) in Patients With Advanced or Metastatic Solid Tumor Cancer | Solid Tumor | P1 | Completed | 192 | Open-label | Selinexor, Acetaminophen |
| NCT02403310 A Study of Selinexor in Combination With Daunorubicin and Cytarabine for Untreated AML | Leukemia, Acute Myeloid Leukemia | P1 | Completed | 21 | Open-label | Selinexor, Daunorubicin, Cytarabine |
| NCT03880123 Selinexor in Combination With Ixazomib for the Treatment of Advanced Sarcoma | Liposarcoma, Malignant Peripheral Nerve Sheath Tumors | P1 | Withdrawn | — | Open-label | Selinexor, Ixazomib |
| NCT02702492 PAK4 and NAMPT in Patients With Solid Malignancies or NHL (PANAMA) | Solid Tumors, NHL | P1 | Terminated | 60 | Open-label | KPT-9274, Niacin ER, Nivolumab |
| NCT02093403 Decitabine and Selinexor in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia | Acute Myeloid Leukemia, Secondary Acute Myeloid Leukemia | P1 | Completed | 25 | Open-label | decitabine, selinexor |
| NCT02137356 Selinexor Combined With Standard Chemoradiation as Neoadjuvant Treatment in Locally Advanced Rectal Cancer | Rectal Neoplasms | P1 | Unknown | 28 | Open-label | standard dose capecitabine, dose-escalated selinexor treatment |
| NCT02212561 Selinexor With Fludarabine and Cytarabine for Treatment of Refractory or Relapsed Leukemia or Myelodysplastic Syndrome | Acute Myeloid Leukemia (AML), Acute Lymphoblastic Leukemia (ALL) | P1 | Completed | 19 | Open-label | Selinexor, Fludarabine, Cytarabine, methotrexate/hydrocortisone/cytarabine |
| NCT02471911 KPT-330 Plus RICE for Relapsed/Refractory Aggressive B-Cell Lymphoma | Diffuse Large B-Cell Lymphoma | P1 | Completed | 22 | Open-label | KPT-330, Rituximab, Etoposide, Carboplatin, Ifosfamide, Dexamethasone |
| NCT01896505 A Phase I Trial to Assess the Effects of Food and Formulation on PK of KPT-330 in Patients With Sarcoma | Sarcoma | P1 | Completed | 54 | RCT, Open-label | KCP-330 |
| NCT02120222 Evaluating SINE KPT-330 in Treating Patients With Melanoma That Cannot Be Removed By Surgery | Recurrent Melanoma | P1 | Completed | 8 | Open-label | selinexor |
| NCT04914845 KPT-9274 in Patients With Relapsed and Refractory Acute Myeloid Leukemia | Acute Myeloid Leukemia, Acute Myeloid Leukemia, in Relapse | P1 | Completed | 16 | Single-blind | KPT-9274 |
| NCT03042819 Study of Selinexor and Doxorubicin in Advanced Soft Tissue Sarcomas | Soft Tissue Sarcoma | P1 | Completed | 25 | Open-label | Selinexor, Doxorubicin |
| NCT02078349 Phase I Study of KPT330 in Asian Patients | Solid Tumors | P1 | Completed | 120 | Open-label | KPT-330 |
| NCT03955783 Venetoclax and Selinexor in Treating Patients With Relapsed or Refractory High Risk Hematologic Malignancies | Diffuse Large B-cell Lymphoma, Acute Myeloid Leukemia | P1 | Completed | 78 | Open-label | Venetoclax, Selinexor |
| NCT01607892 Safety Study of the Selective Inhibitor of Nuclear Export (SINE) KPT-330 in Patients With Advanced Hematological Cancer | Hematological Malignancies | P1 | Completed | 286 | Open-label | KPT-330 |
| NCT02384850 Phase 1 Trial To Evaluate mFOLFOX6 With Selinexor In Patients With Metastatic Colorectal Cancer | Colorectal Neoplasm | P1 | Terminated | 10 | Open-label | Selinexor, Oxaliplatin, 5-FU, Folinic Acid |
| NCT05093608 SELINEXOR in Combination w/Bevacizumab and Atezolizumab in Newly Diagnosed Advanced Hepatocellular Carcinoma | Hepatocellular Carcinoma | P1 | Terminated | 2 | Open-label | Selinexor Pill, Bevacizumab, Atezolizumab |
| NCT02741388 A Phase Ib Study of Oral Selinexor in Adult Patients With Relapsed/Refractory B-cell Lymphoma Receiving R-DHAOx or R-GDP | B-cell Lymphoma | P1 | Completed | 39 | Open-label | selinexor, Rituximab, Dexamethasone, Oxaliplatin, Cisplatin, Cytarabine, Gemcitabine |
| NCT02299518 Selinexor and Chemotherapy in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia | Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Del(5q) | P1 | Completed | 23 | Open-label | mitoxantrone hydrochloride, etoposide, cytarabine, selinexor |
| NCT04519476 Selinexor Treatment for Multiple Myeloma Patients Who Are Refractory to Lenalidomide-containing Therapy. | Refractory Multiple Myeloma | P1 | Unknown | 22 | Open-label | Selinexor, Lenalidomide, Methylprednisolone |
| NCT02831686 A Study to Test the Combination of Selinexor (KPT-330), Ixazomib, and Dexamethasone in Patients With Myeloma | Multiple Myeloma, Relapsed and/or Refractory Multiple Myeloma | P1 | Completed | 18 | Open-label | Selinexor, Ixazomib, Dexamethasone |
| NCT02431364 Trial of Safety and Tolerability of Oral Verdinexor (KPT-335) in Healthy Adults | Healthy | P1 | Terminated | 33 | RCT, Double-blind | Verdinexor |
| NCT02303392 Selinexor and Ibrutinib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Aggressive Non-Hodgkin Lymphoma | Prolymphocytic Leukemia, Recurrent Adult Diffuse Large Cell Lymphoma | P1 | Completed | 34 | Open-label | Selinexor, Ibrutinib |
| NCT04984330 Selinexor for Treatment of Light Chain Amyloidosis With Relapsed/Refractory Disease | Amyloid, Amyloidosis | Early P1 | Withdrawn | — | Open-label | Selinexor, Dexamethasone |
| NCT07215832 Karyopharm Expanded Access Program for Selinexor | Multiple Myeloma, Diffuse Large B-Cell Lymphoma (DLBCL) | AVAILABLE | — | — | selinexor |